Skip to main content

Table 2 Positive rates of 4 tumor markers with single and combined detection in gastric cancer with different stages, location and differentiation

From: Combined use of AFP, CEA, CA125 and CAl9-9 improves the sensitivity for the diagnosis of gastric cancer

 

Cases

Positive cases (%)

AFP

CEA

CA125

CA19-9

Qualitative combined

Stage

      

early stage

30

1 (3.3)

0 (0.0)

2 (6.7)

2 (6.7)

4 (13.3)

advanced stage

119

6 (5.0)

26 (21.8)

19 (16.0)

29 (24.4)

56 (47.1)

χ 2

 

0.156

7.940

1.711

4.557

11.330

P

 

1.000

0.005

0.249

0.042

0.001

Location

      

cardia

13

2 (15.4)

5 (38.5)

1 (7.7)

6 (46.2)

9 (69.2)

gastric body

61

0 (0.0)

12 (19.7)

10 (16.4)

7 (11.5)

21 (34.4)

gastric antrum

70

5 (7.1)

9 (12.9)

10 (14.3)

18 (25.7)

30 (42.9)

multi-site

5

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

χ 2

 

7.504

6.275

1.529

10.630

8.965

P

 

0.056

0.098

0.696

0.016

0.026

Differentiation

      

high

6

1 (16.7)

1 (16.7)

1 (16.7)

2 (33.3)

3 (50.0)

moderate

72

4 (5.6)

12 (16.7)

8 (11.1)

13 (18.1)

28 (38.9)

poor

71

2 (2.8)

13 (18.3)

12 (16.9)

16 (22.5)

29 (40.8)

χ 2

 

2.599

0.070

1.024

1.031

0.303

P

 

0.268

0.930

0.735

0.605

0.839